105 filings
Page 4 of 6
8-K
z6yr7u1
13 Mar 19
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2018 Financial Results
8:00am
8-K
m4zi 47w8
7 Nov 18
Proteon Therapeutics Announces Third Quarter 2018 Financial Results
8:01am
8-K
m25kq7uj iefrzjf
7 Aug 18
Proteon Therapeutics Announces Second Quarter 2018 Financial Results
8:01am
8-K
3odu19n6v
11 Jun 18
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
lfastukv upw0d7rmof
9 May 18
Proteon Therapeutics Announces First Quarter 2018 Financial Results
8:10am
8-K
vy1zdh175p7q
8 May 18
Proteon Therapeutics and Lonza Extend Manufacturing Agreement for Commercial Supply
7:10am
8-K
axu3vot6f
14 Mar 18
Other Events
12:00am
8-K
nlg0ce
14 Mar 18
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
12:00am
8-K
d9nds1ztglt1qwlwh
5 Mar 18
Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase
12:00am
8-K
5qgmdgl
7 Nov 17
Proteon Therapeutics Announces Third Quarter 2017 Financial Results
12:00am
8-K
xay2hsdc86dpafqtv7
22 Aug 17
Entry into a Material Definitive Agreement
12:00am
8-K
po55qxvzr a8
7 Aug 17
Proteon Therapeutics Announces Second Quarter 2017 Financial Results
12:00am
8-K
7b5cq z6ifnd97oor0e
3 Aug 17
Proteon Therapeutics Announces Closing of $22 Million Convertible Preferred Stock Financing
12:00am
8-K
2f837pei xym
26 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
3mly19
23 Jun 17
Entry into a Material Definitive Agreement
12:00am
8-K
sw3vub88tm qyo
22 Jun 17
Proteon Therapeutics Announces $22.0 Million Private Placement
12:00am
8-K
hs8ug0lko
10 May 17
Proteon Therapeutics Announces First Quarter 2017 Financial Results
12:00am
8-K
fjuacm7hc n48swq8x1
2 May 17
Proteon Therapeutics Announces Increase to Enrollment of Ongoing Phase 3 PATENCY-2 Clinical Trial
12:00am
8-K
b2jju86n
22 Mar 17
Regulation FD Disclosure
12:00am
8-K
2ylbxg7bsgy cmg
16 Mar 17
Proteon Therapeutics Announces Full-Year 2016 Financial Results and Changes to the Ongoing Phase 3 PATENCY-2 Clinical Trial
12:00am